What happened
Soaring sales following the launch of its colon-cancer DNA test, Cologuard, led to Exact Sciences’ (NASDAQ:EXAS) shares surging 44.7% higher in 2016, according to S&P Global Market Intelligence.
So what
Colonoscopies may be the gold standard in colon-cancer screening, but they are expensive and invasive, and as a result, a significant population of people who should be getting screened avoid doing so.
